Press Release – Amplyx

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

02/11/2019/by jcalhoon

Antimicrobials Working Group Announces Updates to Leadership Team

01/31/2019/by jcalhoon

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

11/12/2018/by jcalhoon

Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

06/07/2018/by jcalhoon

Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference

06/05/2018/by jnellis

Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

04/30/2018/by jnellis

Amplyx Pharmaceuticals Receives Fourth “Qualified Infectious Disease Product” (QIDP) Designation from the FDA for APX001

03/19/2018/by admin

Amplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference

01/08/2018/by admin

Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017

10/09/2017/by admin

Amplyx Pharmaceuticals Announces Presentations at IDWeek 2017

09/21/2017/by admin